PMID- 22174029
OWN - NLM
STAT- MEDLINE
DCOM- 20120911
LR  - 20151119
IS  - 1439-0795 (Electronic)
IS  - 0176-3679 (Linking)
VI  - 45
IP  - 3
DP  - 2012 May
TI  - A randomized, waiting list-controlled 12-week trial of atomoxetine in adults with 
      ADHD.
PG  - 100-7
LID - 10.1055/s-0031-1291319 [doi]
AB  - BACKGROUND: With the increasing recognition of adult 
      attention-deficit/hyperactivity disorder (ADHD) there is an emerging need to 
      investigate medication in this population. METHODS: In this waiting 
      list-controlled trial, 64 ADHD-patients (mean age 35.8 +/- 8.7 years) were randomly 
      assigned to a daily dosage of up to 80 mg atomoxetine (Atx) or waiting list for 
      12-weeks. Primary outcome was the change of the observer-rated DSM-IV total ADHD 
      score on the Conners' Adult ADHD Rating Scales (CAARSO: L DSM-IV total ADHD 
      score) from baseline to endpoint. Other efficacy measures included selfrated 
      CAARS-S:L DSM-IV total ADHD score, CAARS-O/S:L problems with self-concept and 
      emotional lability score, Wender-Reimherr Adult Attention Defi cit Disorder Scale 
      Emotional Dysregulation Score, and General Activities Score on the Quality of 
      Life Enjoyment and Satisfaction Questionnaire. Efficacy measures were analysed in 
      the per-protocol population. RESULTS: Mean change in CAARS:O-L DSM-IV total ADHD 
      score was -13.1 +/- 7.7 in the Atx vs. -0.4 +/- 4.8 in the control group (p < 0.005). 
      Treatment response ( >/= 30 % reduction) was 60.1 % in the Atx vs. 0 % in the 
      waiting list group. The other efficacy measures also showed significant 
      improvements. The overall incidence of adverse events (AEs) was 70.4 % in the Atx 
      group, the most frequent included fatigue, irritability, nausea and decreased 
      appetite. In Atx-treated patients 18.5 % discontinued early due to AEs. 
      DISCUSSION: Our results suggest that Atx is an effective treatment in adult ADHD. 
      It reduces ADHD core and associated emotional symptoms and increases self-esteem 
      and quality of life. AEs were consistent with those reported in other studies in 
      adult ADHD.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Sobanski, E
AU  - Sobanski E
AD  - Central Institute of Mental Health Mannheim, Department of Psychiatry & 
      Psychotherapy, Medical Faculty Mannheim, University of Heidelberg, Mannheim, 
      Germany. esther.sobanski@zi-mannheim.de
FAU - Sabljic, D
AU  - Sabljic D
FAU - Alm, B
AU  - Alm B
FAU - Baehr, C
AU  - Baehr C
FAU - Dittmann, R W
AU  - Dittmann RW
FAU - Skopp, G
AU  - Skopp G
FAU - Strohbeck-Kuehner, P
AU  - Strohbeck-Kuehner P
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20111215
PL  - Germany
TA  - Pharmacopsychiatry
JT  - Pharmacopsychiatry
JID - 8402938
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Propylamines)
RN  - 57WVB6I2W0 (Atomoxetine Hydrochloride)
SB  - IM
MH  - Adolescent
MH  - Adrenergic Uptake Inhibitors/*administration & dosage/adverse effects
MH  - Adult
MH  - Atomoxetine Hydrochloride
MH  - Attention Deficit Disorder with Hyperactivity/*drug therapy/*psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Satisfaction
MH  - Propylamines/*administration & dosage/adverse effects
MH  - Quality of Life
MH  - Self Concept
MH  - Treatment Outcome
MH  - Waiting Lists
MH  - Young Adult
EDAT- 2011/12/17 06:00
MHDA- 2012/09/12 06:00
CRDT- 2011/12/17 06:00
PHST- 2011/12/17 06:00 [entrez]
PHST- 2011/12/17 06:00 [pubmed]
PHST- 2012/09/12 06:00 [medline]
AID - 10.1055/s-0031-1291319 [doi]
PST - ppublish
SO  - Pharmacopsychiatry. 2012 May;45(3):100-7. doi: 10.1055/s-0031-1291319. Epub 2011 
      Dec 15.